News & Updates

Surgical feeding ostomies (eg gastrostomy) result in significantly higher in-hospital adverse event rates than natural orifice (eg, nasogastric or orogastric) feeding tubes, a study has shown. Thus, policies that require surgical feeding ostomies must be re-evaluated.

A recent study has discovered inappropriate use of faecal immunochemical testing (FIT) in emergency and inpatient settings. Moreover, FIT has led to more gastroenterology consultations but is not independently associated with inpatient endoscopy.

In patients with newly implanted ventricular assist devices (VAD), better leg extensor muscle strength (LEMS) at discharge may suggest a lower risk of rehospitalization, according to a recent Japan study.

While a commonly perceived cause of cancer, stress does not appear to contribute to an increased risk of developing cancer, a study has found.

HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.